MedTrace Logo

Risk Stratification in End Stage Renal Disease (ESRD) - ISAR Study

NCT01152892 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-01-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the use of non-invasive markers of the autonomic function and micro- and macrocirculation to predict mortality and cardiovascular end points in end-stage renal disease patients. Furthermore we aim at getting new insight into the insufficiently understood pathophysiology leading to excessively high cardiovascular and non-cardiovascular mortality in dialysis patients.

Conditions

Sponsors & Collaborators

  • Else Kröner Fresenius Foundation

    collaborator OTHER

  • AIT Austrian Institute of Technology GmbH

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • FH Aachen, University of applied sciences

    collaborator UNKNOWN

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Christoph Schmaderer, M.D., PD · study chief investigator and head of the nephrological laboratory at the department of nephrology of the Klinikum rechts der Isar of the Technical University of Munich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2019-05-31
Completion
2020-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01152892 on ClinicalTrials.gov